Evaluation of Four Commercially Available Epstein-Barr Virus Enzyme Immunoassays with an Immunofluorescence Assay as the Reference Method
Open Access
- 1 January 2003
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 10 (1) , 78-82
- https://doi.org/10.1128/cdli.10.1.78-82.2003
Abstract
Four commercially available enzyme immunoassays (EIAs) (Novitec, Biotest, Virotech, and DiaSorin) were evaluated, with an indirect immunofluorescence assay as the reference method, for Epstein-Barr virus (EBV) VCA (viral capsid antigen) immunoglobulin G (IgG), VCA IgM, or EBNA (EBV nuclear antigen) IgG at three different locations (Homburg, Stuttgart, and Dresden). Serum samples from 66 immunocompetent patients with infectious mononucleosis, 73 patients without prior EBV infection, and 96 patients with past EBV infections and 29 serum samples with possible cross-reactions to other herpesviruses were included. In addition, 25 samples from an extensively pretested panel that is commercially available (Boston Biomedica) were tested. Each sample was tested at only one location. The four EIAs varied considerably in performance. When analyzing for EBV diagnosis, the Novitec assay performed the best, with 4.9% discrepant diagnoses, followed by the Biotest, Virotech, and DiaSorin assays, with 6.8, 11.7, and 14.0% discrepant diagnoses, respectively. On the basis of single-parameter analysis, the Novitec assay also showed the lowest number of discrepant results, with 3.5%, compared with the Virotech, Biotest, and DiaSorin assays, which produced 5.4, 6.4, and 8.6% discrepant results, respectively. VCA assays using affinity-purified native antigens performed better than assays with recombinant or synthetic antigens. The synthetic EBNA-1s showed the lowest concordance with the reference compared to recombinant p72. Commercially available EBV EIAs differed considerably in performance; however, some proved to be reliable and convenient alternatives to the indirect immunofluorescence assay for routine diagnostics. Native antigens, rather than synthetic peptides, are favored for EBV serology testing.Keywords
This publication has 16 references indexed in Scilit:
- Evaluation of a recombinant line blot for diagnosis of Epstein-Barr Virus compared with ELISA, using immunofluorescence as reference methodJournal of Virological Methods, 2001
- Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology.2001
- No correlation in Epstein-Barr virus reactivation between serological parameters and viral load.2000
- The p542 Gene Encodes an Autoantigen that Cross-Reacts with EBNA-1 of the Epstein Barr Virus and which may be a Heterogeneous Nuclear RibonucleoproteinJournal of Autoimmunity, 1997
- Anti-EBNA1/anti-EBNA2 ratio decreases significantly in patients with progression of HIV infectionArchiv für die gesamte Virusforschung, 1996
- Evaluation of 11 enzyme immunoassays for the detection of immunoglobulin M antibodies to Epstein-Barr virusJournal of Virological Methods, 1996
- Difficulties with the serologic diagnosis of infectious mononucleosis: A review of the RCPA quality assurance programsPathology, 1996
- Epstein-Barr virus-induced autoimmune responses. I. Immunoglobulin M autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antigen-1.Journal of Clinical Investigation, 1995
- Expression of Epstein‐Barr virus nuclear antigen 1,2A and 2B in the baculovirus expression system: Serological evaluation of human antibodies to these proteinsJournal of Medical Virology, 1993
- Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosisJournal of Virological Methods, 1988